Although a ctDNA approach to targeted therapy is promising, a multi-arm study of biomarker-targeted therapies in advanced urothelial carcinoma, including FGFR inhibitors in tumors with detected FGFR alterations, PARP inhibitors in tumors with dHRR, and TORC1/2 inhibitors in mTOR/PI3K tumor pathways alterations, did not report improved responses with corresponding ctDNA-detected pathway alterations [131]. Here, PIK3CA is linked to neoplasm.